[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371710-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371710-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","commentary-on-targeted-release-of-a-bispecific-fusion-protein-sirpsiglec-10-by-oncolytic-adenovirus-reinvigorates-tumor-associated-macrophages-to-improve-therapeutic-outcomes-in-solid-tumors","Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors”","","Tumor-associated macrophages (TAMs), long used by cancers to evade immune detection, can be reprogrammed into strong antitumor effectors through viral engineering. Zhang et al introduced an adenovirus (Adv-mSS) blocking two “don’t eat me” signals, CD47 and CD24, to convert immunosuppressive TAMs into tumor-engulfing cells and restore CD8 T-cell responses. This approach enhances both innate and adaptive antitumor immunity and addresses limitations of current immunotherapies in solid tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/commentary-on-targeted-release-of-a-bispecific-fusion-protein-sirpsiglec-10-by-oncolytic-adenovirus-reinvigorates-tumor-associated-macrophages-to-improve-therapeutic-outcomes-in-solid-tumors/371710/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/commentary-on-targeted-release-of-a-bispecific-fusion-protein-sirpsiglec-10-by-oncolytic-adenovirus-reinvigorates-tumor-associated-macrophages-to-improve-therapeutic-outcomes-in-solid-tumors/371710.png","ImageObject",300,407,{"name":42,"@type":43},"Stanley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main immunological problem the commentary addresses?","Question",{"text":63,"@type":64},"Cancer-driven immune evasion is mediated in part by TAMs that suppress antitumor immunity, preventing effective immune detection and response.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What does Adv-mSS target to enhance phagocytosis?",{"text":68,"@type":64},"Adv-mSS blocks two inhibitory pathways by targeting the CD47 and CD24 “don’t eat me” signals, thereby restoring macrophage phagocytic activity.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is TAM–CD8 synergy important in the reported therapeutic effect?",{"text":72,"@type":64},"The commentary states that Adv-mSS efficacy depends on both TAMs and CD8+ T cells, highlighting the need for coordination between innate and adaptive immunity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371710,1790828828,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":30,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":30,"preview_urls":145},2336477405376,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Open access Commentary  \n Commentary on “Targeted release of a  \nbispecific fusion protein SIRPα/ Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors”  \nMarc Lecoultre,1 Aya El Helali  2  \nTo cite: Lecoultre M, El Helali A. Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in  \nsolid tumors”. Journal for ImmunoTherapy of Cancer 2025;13:e012218 . doi:10 . 1136/ jitc-2025-012218  \nAccepted 04 June 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Department of Medical Oncology and Hematology, University Hospital Zurich, Zürich, Switzerland 2Department of Clinical Oncology, Centre of Cancer Medicine, The University of Hong Kong, Hong Kong, Hong Kong  \nCorrespondence to  \nDr Aya El Helali; ahelali@hku. hk  \nABSTRACT  \nTumor-associated macrophages (TAMs), long exploited by cancers to evade immune detection, can now be reprogrammed into potent antitumor effectors through cutting-edge viral engineering. In a landmark study published in the Journal for Immunotherapy of Cancer, Zhang et al introduced an innovative adenovirus, Adv-mSS, that blocks two critical “don’t eat me” signals, CD47 and CD24, used by tumors to paralyze macrophage activity. By converting immunosuppressive TAMs into tumor-engulfing predators and reigniting CD8 T-cell response, Adv-mSS eradicated tumors across multiple preclinical models. This strategy offers a promising avenue for activating both innate and adaptive immunity against cancer and may address key limitations of current immunotherapies.  \nImmunotherapy has transformed oncology, exemplified by checkpoint inhibitors targeting Programmed Death 1 (PD-1)/ Programmed Death Ligand 1 (PD-L1) and cytotoxic T Lymphocyte-Associated Protein 4 (CTLA-4) in melanoma and lung cancer. However, their limited efficacy in other solid tumors underscores the need for strategies that engage innate and adaptive immunity. Tumor-associated macrophages (TAMs), abundant in many malignancies, are pivotal regulators of antitumor immunity due to their phagocytic activity, capacity to remodel the tumor microenvironment, and ability to prime CD8+T cells.1 Recent preclinical and clinical studies emphasize TAMs as therapeutic targets, given their dual role in promoting immunosuppression or antitumor activity, depending on polarization. Zhang et al have now engineered an adenovirus (AdvmSS) that enhances TAM phagocytosis by dual targeting of the CD47 and CD24 receptors, offering a novel approach to amplify antitumor immunity.  \nPhagocytosis is regulated by a delicate balance between “eat-me” and “don’t eatme” signals exploited by cancer cells to evade immune detection. Among these, CD47 and CD24 have emerged as critical mediators of immune evasion. CD47 is a ubiquitously expressed protein that binds to signal regulatory protein alpha (SIRPα) on macrophages, effectively inhibiting phagocytosis.2 Furthermore, elevated CD47 levels correlate with poor prognosis across cancers.3 In clinical trials, targeting CD47 showed promising results in a phase Ib/II trial in combination with cetuximab in Kirsten Rat Sarcoma Virus (KRAS) wild-type colorectal cancers.4 However, systemic CD47 blockade risks anemia due to its expression on red blood cells. Similarly, CD24 interacts with macrophage Siglec-10 to suppress phagocytosis, and preclinical studies highlight its potential as a therapeutic target. Targeting this axis has also demonstrated potential in preclinical studies as well.5 Despite these advances, single target approaches often fail due to redundant signaling pathways. To address this, Zhang et al designed Adv-mSS, an oncolytic adenovirus encoding soluble decoys for SIRPα and Siglec-10.6 SIRPα and Siglec-10 are two surface proteins expressed b","cbCaigVkSV0K86Pl","https://ap.wps.com/l/cbCaigVkSV0K86Pl","pdf",765121,"English","# ABSTRACT\n## TAMs and immunotherapy context\n## CD47 and CD24 immune evasion axis\n## Adv-mSS dual targeting mechanism\n## Preclinical findings and immune synergy","[{\"question\":\"What is the main immunological problem the commentary addresses?\",\"answer\":\"Cancer-driven immune evasion is mediated in part by TAMs that suppress antitumor immunity, preventing effective immune detection and response.\"},{\"question\":\"What does Adv-mSS target to enhance phagocytosis?\",\"answer\":\"Adv-mSS blocks two inhibitory pathways by targeting the CD47 and CD24 “don’t eat me” signals, thereby restoring macrophage phagocytic activity.\"},{\"question\":\"Why is TAM–CD8 synergy important in the reported therapeutic effect?\",\"answer\":\"The commentary states that Adv-mSS efficacy depends on both TAMs and CD8+ T cells, highlighting the need for coordination between innate and adaptive immunity.\"}]","Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors” | PDF",1790192678,[146,150,154],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/876125f7a4741f458838af8ffc1a11a7.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62e965e2c343d31d8c67f54e5ca78fda.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0db38ea101b425f09c7850a6e57bb22.webp",981,1308]